P53 an oncogene or tumor suppressor gene: A confusion

Abstract

p53 is a widely studied oncogene to date. In most cancer types, p53 is highly mutated and considered a potential target for cancer; however, there is no clinically valid candidate in the market that targets p53. There is still confusion about whether p53 promotes cancer? Or not as of now, it is believed that it is a tumor suppressor gene. A lot of studies have been done, and many scientists doubt its functionality. This mini-review will discuss some recent findings on the p53 mutations, their association with cancer, and with some insight on p53 isomers.

References

1. P. Monti, P. Menichini, A. Speciale, G. Cutrona, F. Fais, E. Taiana, A. Neri, R. Bomben, M. Gentile, V. Gattei, M. Ferrarini, F. Morabito, G. Fronza, Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?, Frontiers in Oncology. 10 (2020) 2313. https://doi.org/10.3389/fonc.2020.593383.
2. D.E. Moulder, D. Hatoum, E. Tay, Y. Lin, E.M. McGowan, The roles of p53 in mitochondrial dynamics and cancer metabolism: The pendulum between survival and death in breast cancer?, Cancers. 10 (2018). https://doi.org/10.3390/cancers10060189.
3. F. Mantovani, L. Collavin, G. del Sal, Mutant p53 as a guardian of the cancer cell, Cell Death and Differentiation. 26 (2019) 199–212. https://doi.org/10.1038/s41418-018-0246-9.
4. F. Mantovani, D. Walerych, G. del Sal, Targeting mutant p53 in cancer: a long road to precision therapy, FEBS Journal. 284 (2017) 837–850. https://doi.org/10.1111/febs.13948.
5. M.P. Kim, G. Lozano, Mutant p53 partners in crime, Cell Death and Differentiation. 25 (2018) 161–168. https://doi.org/10.1038/cdd.2017.185.
6. F. Mantovani, L. Collavin, G. del Sal, Mutant p53 as a guardian of the cancer cell, Cell Death and Differentiation. 26 (2019) 199–212. https://doi.org/10.1038/s41418-018-0246-9.
7. Genes, (n.d.). https://portal.gdc.cancer.gov/genes/ENSG00000141510 (accessed May 1, 2021).
8. T. Soussi, K.G. Wiman, TP53: An oncogene in disguise, Cell Death and Differentiation. 22 (2015) 1239–1249. https://doi.org/10.1038/cdd.2015.53.
9. X. Wang, Q. Sun, TP53 mutations, expression and interaction networks in human cancers, Oncotarget. 8 (2017) 624–643. https://doi.org/10.18632/oncotarget.13483.
10. J. Liu, C. Zhang, W. Hu, Z. Feng, Tumor suppressor p53 and metabolism, Journal of Molecular Cell Biology. 11 (2019) 284–292. https://doi.org/10.1093/jmcb/mjy070.
11. X. Yue, Y. Zhao, Y. Xu, M. Zheng, Z. Feng, W. Hu, Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy, Journal of Molecular Biology. 429 (2017) 1595–1606. https://doi.org/10.1016/j.jmb.2017.03.030.
12. C. Pitolli, Y. Wang, M. Mancini, Y. Shi, G. Melino, I. Amelio, Do mutations turn p53 into an oncogene?, International Journal of Molecular Sciences. 20 (2019). https://doi.org/10.3390/ijms20246241.
13. M. Olivier, M. Hollstein, P. Hainaut, TP53 mutations in human cancers: origins, consequences, and clinical use., Cold Spring Harbor Perspectives in Biology. 2 (2010). https://doi.org/10.1101/cshperspect.a001008.
14. L. Ding, G. Getz, D.A. Wheeler, E.R. Mardis, M.D. McLellan, K. Cibulskis, C. Sougnez, et al., Somatic mutations affect key pathways in lung adenocarcinoma, Nature. 455 (2008) 1069–1075. https://doi.org/10.1038/nature07423.